One thing we can take away - OTAT meeting results had nothing to do with Novartis walking away.
They've walked away for other reasons - that's their business and their right to do so.
But, the conjecture of them knowing a bad OTAT result and this was the reason they've walked away is BS!
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-46
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.045(2.98%) |
Mkt cap ! $1.672B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $8.307M | 5.669M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 151320 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 55652 | 2 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |